Vivos awaits Nasdaq confirmation on equity compliance; warns of delisting risk if capital insufficient

Vivos Therapeutics, Inc.

Company believes it met $2.5M minimum equity requirement by March 19, 2024, via capital raises in Nov 2023 and Feb 2024.
Nasdaq has not yet confirmed compliance; will monitor ongoing compliance at next periodic report.
Company expects to need additional equity capital to maintain compliance; failure could lead to delisting.
Delisting would materially harm stock price, liquidity, capital raising ability, and reputation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.